Clinical Trial

Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

Study acronym: RACEMATE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
RACEMATE is a phase 2b, multicentre, randomised, double-blinded, placebo-controlled study designed to explore the efficacy and mechanism of action of tezepelumab in adults with eosinophilic granulomatosis with polyangiitis (EGPA).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-01-19; most recent amendment 2026-04-23.
Status change: Enrolling by Invitation → Active, Not Recruiting 2026-04-23
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-02-02
Trial Details
NCT Number NCT06230354
Lead Sponsor Imperial College London
Collaborators: AstraZeneca
Conditions EGPA - Eosinophilic Granulomatosis With Polyangiitis
Enrollment 42 participants
Start Date 2024-05-15
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-29